80 / 89
80
28.
Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE,
Szubert AJ, et al. Cyclophosphamide, thalidomide, and
dexamethasone (CTD) as initial therapy for patients with
multiple
myeloma
unsuitable
for
autologous
transplantation. Blood 2011;118:1231-8.
29.
Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ,
Navarro Coy N, et al. Cyclophosphamide, thalidomide,
and dexamethasone as induction therapy for newly
diagnosed multiple myeloma patients destined for
autologous stem-cell transplantation: MRC Myeloma IX
randomized trial results. Haematologica 2012;97:442-50.
30.
Khan ML, Reeder CB, Kumar SK, Lacy MQ, Reece DE,
Dispenzieri
A,
et
al.
A
comparison
of
lenalidomide/dexamethasone
versus
cyclophosphamide/lenalidomide/dexamethasone versus
cyclophosphamide/
bortezomib/dexamethasone
in
newly diagnosed multiple myeloma. Br J Haematol
2012;156:326-33.
31.
Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N,
et al. Bortezomib, dexamethasone, cyclophosphamide and
lenalidomide combination for newly diagnosed multiple
myeloma: phase 1 results from the multicenter
EVOLUTION study. Leukemia 2010;24:1350-6.
32.
Corso A, Barbarano L, Mangiacavalli S, Spriano M,
Alessandrino EP, Cafro AM, et al. Bortezomib plus
dexamethasone can improve stem cell collection and
overcome the need for additional chemotherapy before
autologous transplant in patients with myeloma. Leuk
Lymphoma 2010;51:236-42.
33.
Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan
GJ. The combination of cyclophosphamide, velcade and
dexamethasone induces high response rates with
comparable toxicity to velcade alone and velcade plus
dexamethasone. Haematologica 2007;92:1149-50.